All Stories

  1. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
  2. Advax delta inulin adjuvant accelerates humoral anti-influenza response
  3. Delta inulin alone or combined with CpG oligonucleotide enhances antibody‐dependent influenza vaccine protection in mice and nonhuman primate newborns
  4. One Health adjuvant selection for vaccines against zoonotic infections
  5. Magnetoencephalography Reveals Neuroprotective Effects of COVID-19 Vaccination in Non-Human Primates
  6. Virus-like particle-based vaccines targeting theAnophelesmosquito salivary protein, TRIO
  7. Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant
  8. MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity
  9. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
  10. Dendritic cell–specific intercellular adhesion molecule‐3‐grabbing nonintegrin (DC‐SIGN) is a cellular receptor for delta inulin adjuvant
  11. Structure–Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist
  12. Structure-activity relationship in NOD2 agonistic muramyl dipeptides
  13. Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines
  14. Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
  15. Structure−Activity Relationships Towards the Identification of High-Potency Selective Human Toll-Like Receptor-7 Agonist
  16. Safety and immunogenicity of an adjuvanted recombinant spike protein‐based severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine, SpikeVet™, in selected Carnivora, Primates and Artiodactyla in Australian zoos
  17. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates
  18. Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines
  19. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial
  20. A Multiseason Randomized Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants With Chronic Disease or Older Age
  21. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants
  22. Structure-Activity Relationship in NOD2 Agonistic Muramyl Dipeptides
  23. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection
  24. Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice
  25. An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice
  26. Author Correction: An intranasal vaccine comprising SARS‑CoV‑2 spike receptor‑binding domain protein entrapped in mannose‑conjugated chitosan nanoparticle provides protection in hamsters
  27. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques
  28. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters
  29. Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates
  30. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
  31. Detection, characterization, and persistence of Campylobacter hepaticus, the cause of spotty liver disease in layer hens
  32. Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants
  33. Lignin nanoparticles as a novel carrier for efficacious delivery of toll like receptor 7/8 agonist: Physicochemical and in-vitro evaluation
  34. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics
  35. An alternative protein-based vaccine against COVID-19
  36. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice
  37. Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
  38. Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates
  39. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation
  40. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
  41. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
  42. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
  43. Narrative Review: Obesity, Type 2 DM and Obstructive Sleep Apnoea—Common Bedfellows
  44. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trial
  45. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase
  46. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates
  47. Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis
  48. Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice
  49. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters
  50. Identification of adjuvants for γδ T cells in response to a novel M. tuberculosis vaccine antigen
  51. Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255
  52. Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model
  53. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
  54. A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats
  55. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
  56. Potential COVID-19 therapies from computational repurposing of drugs and natural products against the SARS-CoV-2 helicase
  57. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
  58. Combined delivery of TLR2 and TLR7 agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in mice
  59. Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants
  60. Artificial Intelligence in Vaccine and Drug Design
  61. Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates
  62. A Spike protein-based subunit SARS-CoV-2 vaccine for pets: safety, immunogenicity, and protective efficacy in juvenile cats
  63. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
  64. An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection
  65. Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
  66. An Advax-adjuvanted Inactivated Cell-culture Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-flavivirus Antibodies and T-cell Immunity and Provides Single Dose Protection
  67. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
  68. An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2
  69. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
  70. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
  71. Author Correction: In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
  72. Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent
  73. A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection
  74. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
  75. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection
  76. A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization
  77. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
  78. Impaired Ca2+ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment
  79. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
  80. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
  81. Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction
  82. Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines
  83. Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets
  84. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity
  85. Combination adjuvants enhance recombinant protein vaccine protection against fungal infection
  86. Accelerated vaccine induction of IgM neutralising antibody enables vaccine protection against same day lethal influenza virus challenge
  87. Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice
  88. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein
  89. Strategies for active and passive pediatric RSV immunization
  90. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles
  91. TLR2 Agonistic Small Molecules: Detailed Structure–Activity Relationship, Applications, and Future Prospects
  92. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability
  93. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis
  94. Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity
  95. Advax adjuvant formulations promote protective immunity against aerosolMycobacterium tuberculosisin the absence of deleterious inflammation and reactogenicity
  96. Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance
  97. Flavivirus DNA Vaccine Design and Adjuvant Selection
  98. An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein
  99. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection
  100. Adjuvant selection impacts the correlates of vaccine protection against Ebola infection
  101. Influence of Oxidation Degree on the Physicochemical Properties of Oxidized Inulin
  102. Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies
  103. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
  104. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependant protection against pulmonary tuberculosis
  105. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology
  106. Prediction of novel mouse TLR9 agonists using a random forest approach
  107. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
  108. Doxorubicin-Loaded Delta Inulin Conjugates for Controlled and Targeted Drug Delivery: Development, Characterization, and In Vitro Evaluation
  109. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice
  110. Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery
  111. Review of polysaccharide particle-based functional drug delivery
  112. MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus
  113. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity
  114. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy
  115. Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy
  116. Use of adjuvants to make neonatal vaccines more effective
  117. Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
  118. Calcium Signaling As a Therapeutic Target for Liver Steatosis
  119. A Microfluidic Tumor‐on‐a‐Chip for Assessing Multifunctional Liposomes' Tumor Targeting and Anticancer Efficacy
  120. Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
  121. Microfluidic formation of core-shell alginate microparticles for protein encapsulation and controlled release
  122. Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample
  123. Synthesis and characterization of a novel inulin hydrogel crosslinked with pyromellitic dianhydride
  124. Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge
  125. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
  126. The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients
  127. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge
  128. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy
  129. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats
  130. Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures
  131. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection
  132. Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection
  133. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant
  134. Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant
  135. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs
  136. Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology
  137. Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine
  138. Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines
  139. Molecular Adjuvants for DNA Vaccines
  140. Vaccine Adjuvant Nanotechnologies
  141. ALMS1 acts as a critical molecular switch that controls Insulin-stimulated glucose transport in adipocytes
  142. Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens
  143. Influenza immunization during pregnancy: Benefits for mother and infant
  144. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
  145. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant
  146. Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
  147. Physical characterization and in silico modeling of inulin polymer conformation during vaccine adjuvant particle formation
  148. Vaxine
  149. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology
  150. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients
  151. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes
  152. Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy
  153. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
  154. SARS coronavirus infections of the lower respiratory tract and their prevention
  155. Molecular mechanisms for enhanced DNA vaccine immunogenicity
  156. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety
  157. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
  158. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single–dose influenza vaccine protection
  159. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema
  160. Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines
  161. Novel nanoparticle vaccines for Listeriosis
  162. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene
  163. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease
  164. Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine
  165. Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: Atomic force microscopy and static molecular modelling
  166. A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection
  167. Pulmonary immunisation
  168. Characterisation of adjuvants for use in dromedary immunisation
  169. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology
  170. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
  171. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study
  172. Editorial (Thematic Issue: The Coming of Age of DNA Vaccines)
  173. Plasmids Encoding Protein Aggregation Domains Act As Molecular Adjuvants for DNA Vaccines
  174. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection
  175. In Silico Structural Homology Modelling and Docking for Assessment of Pandemic Potential of a Novel H7N9 Influenza Virus and Its Ability to Be Neutralized by Existing Anti-Hemagglutinin Antibodies
  176. Inulin isoforms differ by repeated additions of one crystal unit cell
  177. Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant
  178. Gamma ray sterilization of delta inulin adjuvant particles (Advax™) makes minor, partly reversible structural changes without affecting adjuvant activity
  179. Sugar-Based Immune Adjuvants for Use in Recombinant, Viral Vector, DNA and Other Styles of Vaccines
  180. Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics
  181. Chiral Self-Assembly of Designed Amphiphiles: Influences on Aggregate Morphology
  182. An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody
  183. Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia
  184. The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions
  185. Vaccine adjuvants: in search of new paradigms
  186. Vaccine adjuvant safety: the elephant in the room
  187. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing
  188. Flu watch
  189. Computational vaccinology and the ICoVax 2012 workshop
  190. JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8+ T Cells and Pre-Exposure Neutralizing Antibody
  191. Systems Immunology, Vaccine Adjuvant
  192. Unconventional Vaccines: Progress and Challenges
  193. A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle
  194. Immunotherapy – 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy
  195. The future of human DNA vaccines
  196. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses
  197. BBS-Induced Ciliary Defect Enhances Adipogenesis, Causing Paradoxical Higher-Insulin Sensitivity, Glucose Usage, and Decreased Inflammatory Response
  198. Characterization in rabbits & nonhuman primates of the neutralizing antibody response elicited by DNA & protein vaccination with SIVmac251 & SIVsmE660
  199. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant
  200. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses
  201. Report from the field
  202. Analysis of the hydrolysis of inulin using real time 1H NMR spectroscopy
  203. Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes
  204. Technologies for enhanced efficacy of DNA vaccines
  205. Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
  206. Observation of the keto tautomer of d-fructose in D2O using 1H NMR spectroscopy
  207. Dyspnea in Pulmonary Arterial Hypertension
  208. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets
  209. Effects of perindopril–indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy
  210. Pediatric influenza immunization
  211. Serological responses following influenza A H1N1 2009 infection in adults
  212. Carbohydrate-based immune adjuvants
  213. The Vaccine Renaissance
  214. Challenges in improving influenza vaccine protection in the elderly
  215. World Vaccine Congress Asia 2011 (June 20-24, 2011, Singapore)
  216. Immunome Research-Five Years On
  217. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations
  218. Alström syndrome: insights into the pathogenesis of metabolic disorders
  219. Delta inulin: a novel, immunologically active, stable packing structure comprising  -D-[2 -> 1] poly(fructo-furanosyl)  -D-glucose polymers
  220. Lessons learned from the H1N1 2009 pandemic
  221. Management of dyspnea in advanced pulmonary arterial hypertension
  222. Aldose Reductase Gene Polymorphisms and Diabetic Retinopathy Susceptibility
  223. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus
  224. Sequence Variation in DDAH1 and DDAH2 Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes
  225. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses
  226. Association Between Erythropoietin Gene Polymorphisms and Diabetic Retinopathy
  227. Common Sequence Variation in theVEGFAGene Predicts Risk of Diabetic Retinopathy
  228. Focus on Influenza vaccines
  229. P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants
  230. Diabetic Retinopathy Is Associated With Elevated Serum Asymmetric and Symmetric Dimethylarginines
  231. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
  232. Pharmacological Management of Endocrine Conditions in the Elderly Patient
  233. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5
  234. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
  235. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial
  236. Antisaccade deficits in subjects either genetically or clinically at risk for schizophrenia
  237. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor γ agonist alleviates the symptoms of DSS-induced colitis
  238. Freeing vaccine adjuvants from dangerous immunological dogma
  239. Data Extraction for Improved Prediction Outcomes in Organ Transplantation — A Hybrid Approach
  240. Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis
  241. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity
  242. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice
  243. Bioinformatics for study of autoimmunity
  244. PREDNOD, a prediction server for peptide binding to the H-2g7haplotype of the non-obese diabetic mouse
  245. Type 1 Diabetes: Immunology and Genetics
  246. The Transcriptional Landscape of the Mammalian Genome
  247. Temporal regulation of the human immune system
  248. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
  249. Assessment of cardiovascular disease risk factors and diabetes mellitus in Australian prisons: is the prisoner population unhealthier than the rest of the Australian population?
  250. Information technologies for vaccine research
  251. Immunoinformatics and its relevance to understanding human immune disease
  252. Hypothyroidism and hyponatraemia in the hospital setting
  253. Dexamethasone Infusion Testing in the Diagnosis of Cushing's Syndrome
  254. A Hybrid Decision Tree – Artificial Neural Networks Ensemble Approach for Kidney Transplantation Outcomes Prediction
  255. Virtual models of the HLA class I antigen processing pathway
  256. Identification of Key β Cell Gene Signaling Pathways Involved in Type 1 Diabetes
  257. The Power of an Integrated Informatic and Molecular Approach to Type 1 Diabetes Research
  258. Addison's disease presenting in four adolescents with type 1 diabetes
  259. Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications
  260. Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses
  261. Elevated Lymphocyte Expression of CLIP Is Associated with Type 1 Diabetes and May Be a Useful Marker of Autoimmune Susceptibility
  262. A rash: Part 1
  263. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
  264. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
  265. Vaccine adjuvants: Current state and future trends
  266. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
  267. The perils of untimed serum cortisol measurement
  268. Identification of "pathologs" (disease-related genes) from the RIKEN mouse cDNA dataset using human curation plus FACTS, a new biological information extraction system
  269. A swollen abdomen: Part 1
  270. Systematic genome‐wide approach to positional candidate cloning for identification of novel human disease genes
  271. VIRAL ENCEPHALITIS IN HUMANS
  272. Use of Artificial Neural Networks in the Prediction of Kidney Transplant Outcomes
  273. FREP: a database of functional repeats in mouse cDNAs
  274. Autoimmune Diabetes in the NOD Mouse: An Essential Role of Fas‐FasL Signaling in β Cell Apoptosis
  275. Prevention of Autoimmune Diabetes through Immunostimulation with Q Fever Complement‐Fixing Antigen
  276. The Role of Endoplasmic Reticulum Stress in Nonimmune Diabetes: NOD.k iHEL, a Novel Model of β Cell Death
  277. Allergen databases
  278. Computational tools for the study of allergens
  279. Corrigendum
  280. Cytokine-Related Genes Identified From the RIKEN Full-Length Mouse cDNA Data Set
  281. Inferring Higher Functional Information for RIKEN Mouse Full-Length cDNA Clones With FACTS
  282. Identification of Novel “Pathologs” (Human Disease-Related Gene Candidates) From the RIKEN Full-Length Mouse cDNA Data Set
  283. Mechanisms of Accelerated Immune-Mediated Diabetes Resulting from Islet β Cell Expression of a Fas Ligand Transgene
  284. Bioinformatics for characterisation of allergens, allergenicity and allergic crossreactivity
  285. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter‐regulator
  286. Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus
  287. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
  288. Pregnancy‐associated osteoporosis with hypercalcaemia
  289. Evidence from twins for acquired cellular immune hyperactivity in type 1 diabetes
  290. Computational immunology: The coming of age
  291. Prediction of promiscuous peptides that bind HLA class I molecules
  292. Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease
  293. The Role of Fas Ligand in Beta Cell Destruction in Autoimmune Diabetes of NOD Mice
  294. Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study
  295. Severe diabetic retinopathy: a rare complication of acromegaly
  296. Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus
  297. Use of Artificial Neural Networks in Improving Renal Transplantation Outcomes
  298. Severe diabetic retinopathy: a rare complication of acromegaly
  299. Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding
  300. Towards a unified model of neuroendocrine–immune interaction
  301. Macrophage Migration Inhibitory Factor: A Critical Neurohumoral Mediator
  302. Molecular immunology databases and data repositories
  303. Macrophage Migration Inhibitory Factor (MIF): A Critical Neurohumoral Mediator
  304. DIURNAL RHYTHMS OF PRO-INFLAMMATORY CYTOKINES: REGULATION BY PLASMA CORTISOL AND THERAPEUTIC IMPLICATIONS
  305. The Chronobiology of Human Cytokine Production
  306. Danazol in the treatment of a systemic lupus erythematosus (SLE)‐like illness associated with deficiency of the fourth component of complement
  307. HLA Class II-associated polymorphism of interferon-γ production implications for HLA-disease association
  308. Evidence for the Viral Aetiology of IDDM
  309. A strategy for prediction of peptide binding affinity for the human peptide transporter
  310. The paradoxical association between immunodeficiency and autoimmunity: Comment on he article by Atkinson
  311. Th1 and Th2: swinging to a hormonal rhythm
  312. Cytokine-based human whole blood assay for the detection of antigen-reactive T cells
  313. T-cell receptor signal sequences
  314. HLA-matched control subjects are essential in studies of susceptibility to IDDM
  315. Difficulties and dangers of vaccination strategies for asthma and other autoimmune disorders
  316. Whole Blood Assays and the Influence of Circadian Rhythmicity on Human Cytokine Measurement
  317. Immunoinformatics—The New Kid in Town
  318. Use of Artificial Neural Networks in Improving Renal Transplantation Outcomes
  319. The Future for Computational Modelling and Prediction Systems in Clinical Immunology